Key Takeaways
- As of September 2026, compounded semaglutide had a month-1 median of $197 and compounded tirzepatide $299 across 14 telehealth providers each (Compounded GLP-1 Price Index, September 3, 2026), while manufacturer self-pay brand prices have fallen to $149 to $449 a month, so the cash gap is far smaller than it was in 2024
- Manufacturer patient assistance programs can provide free medication for patients earning under 400 percent of the federal poverty level (roughly $63,840 for an individual in 2026); check each program's current product list, because Wegovy's and Zepbound's inclusion could not be confirmed for this update
- Cash-pay telehealth platforms bypass insurance entirely, offering prescriptions and medication for flat monthly fees
- Canadian pharmacy imports and medical tourism carry legal risks that most clinicians advise against despite lower prices
The short answer
Seven pathways exist to access weight loss medication without insurance in 2026: compounded GLP-1s through telehealth (month-1 medians of $197 for semaglutide and $299 for tirzepatide, September 2026), manufacturer patient assistance programs (free for qualifying low-income patients), manufacturer self-pay and cash-pay pharmacy purchases ($149 to $449 a month at September 2026 self-pay prices), discount card programs, clinical trial enrollment, state pharmacy assistance programs, and nonprofit medication access foundations.
Table of contents
- What most articles get wrong about uninsured access
- The seven pathways ranked by cost and accessibility
- Pathway 1: Compounded semaglutide and tirzepatide
- Pathway 2: Manufacturer patient assistance programs
- Pathway 3: Cash-pay retail pharmacy purchases
- Pathway 4: Prescription discount cards and coupons
- Pathway 5: Clinical trial enrollment
- Pathway 6: State pharmaceutical assistance programs
- Pathway 7: Nonprofit medication access foundations
- The decision tree: which pathway fits your situation
- Why Canadian pharmacies and medical tourism fail the risk-benefit test
- FormBlends clinical pattern: what we see in 2,400+ uninsured patient journeys
- Cheapest weight-loss drugs without insurance, September 2026
- Manufacturer self-pay programs
- Patient assistance in 2026
- Medicare and Medicaid in 2026
- Low-cost prescriber routes
- FAQ
- Sources
What most articles get wrong about uninsured access
Most published guides treat "without insurance" as a single category. This creates a dangerous oversimplification.
See transparent compounded pricing
Review compounded GLP-1 pricing and what provider-reviewed care includes, with no surprises at checkout.
Try the Cost Calculator →A 28-year-old self-employed graphic designer earning $75,000 annually has completely different access options than a 52-year-old between jobs earning $22,000. The first has cash-flow capacity but no coverage. The second qualifies for patient assistance programs the first doesn't.
The error appears in headlines like "GLP-1s cost $1,000+ without insurance" (true of list prices but ignores manufacturer self-pay at $149 to $449 and compounded medians of $197 to $299) or "Patient assistance makes medication free" (true only for patients under 400 percent FPL who clear the paperwork, and only for products on each program's current list).
Income level, employment status, state of residence, and medical diagnosis all determine which pathways actually work. A patient in Massachusetts has access to state programs a patient in Alabama doesn't. A patient with documented type 2 diabetes qualifies for assistance a patient seeking weight loss alone may not.
The correct framing is pathway-specific. Each route has distinct eligibility gates, cost structures, and trade-offs. The question isn't "how much does it cost without insurance" but "which of the seven pathways am I eligible for, and what does each one actually require?"
The seven pathways ranked by cost and accessibility
| Pathway | Monthly cost | Eligibility barrier | Time to access | Legal risk |
|---|---|---|---|---|
| Compounded GLP-1 telehealth | Month-1 medians $197 (semaglutide) and $299 (tirzepatide); ranges $88 to $470 | BMI 27+ with comorbidity or BMI 30+ | 24 to 72 hours | None (U.S. licensed); not FDA approved |
| Manufacturer patient assistance | $0 (free) | Income under 400% FPL, no Rx coverage | 5 to 14 days | None |
| Manufacturer self-pay or cash-pay pharmacy | $149 to $449 at manufacturer self-pay prices; about $1,028 to $1,349 at list | Prescription only | Same day to a few days | None |
| Discount card programs | Little added value for brand GLP-1s now that self-pay prices exist; large savings on generics such as phentermine (about $16) | Prescription only | Same day | None |
| Clinical trial enrollment | $0 (free) | Trial-specific criteria | 2 to 8 weeks | None |
| State pharmaceutical assistance | $0 to $50 | State residency, income limits | 10 to 30 days | None |
| Nonprofit medication foundations | $0 to $100 | Disease-specific, income limits | 14 to 45 days | None |
The table reveals the access paradox: the cheapest options (patient assistance, trials, state programs) have the longest wait times and strictest eligibility. The fastest options (compounded telehealth, cash pharmacy) cost the most or require immediate payment.
Most patients without insurance use a combination strategy. Start with compounded telehealth for immediate access while applying for patient assistance programs in parallel. If assistance approves, switch to free brand-name medication. If denied, continue with compounded or explore state programs.
Pathway 1: Compounded semaglutide and tirzepatide
Compounded GLP-1 medications represent the fastest, most accessible pathway for patients without insurance.
How it works: A licensed telehealth provider evaluates you remotely (video or asynchronous), writes a prescription for compounded semaglutide or tirzepatide, and a 503A or 503B compounding pharmacy ships the medication directly to your address. The entire process happens outside the insurance system.
Pricing (Compounded GLP-1 Price Index, September 3, 2026):
- Compounded semaglutide: month-1 (0.25 mg) median $197 across 14 telehealth providers, range $88 to $299; month-4 (1 mg) median $224
- Compounded tirzepatide: month-1 (2.5 mg) median $299 across 14 providers, range $149 to $470; month-4 (5 mg) median $299
- Live figures and the provider list are in the Compounded GLP-1 Price Index
Eligibility:
- BMI 27 or higher with weight-related comorbidity (hypertension, prediabetes, sleep apnea), or BMI 30 or higher
- No contraindications (personal or family history of medullary thyroid carcinoma, multiple endocrine neoplasia syndrome type 2, severe gastroparesis)
- Age 18 or older
Time to access: Most telehealth platforms complete evaluation and ship medication within 24 to 72 hours of initial consultation.
Key differences from brand-name: Compounded semaglutide is chemically identical to the active ingredient in Wegovy but prepared by a compounding pharmacy rather than manufactured by Novo Nordisk. It's drawn from a vial with a syringe rather than delivered via pre-filled pen. It's not FDA-approved as a finished drug product (the active ingredient is FDA-approved, but the compounded preparation is not).
The FDA permitted copies of semaglutide and tirzepatide while they were on its shortage list. That ended for tirzepatide on December 19, 2024 and for semaglutide on February 21, 2025, and the Fifth Circuit upheld the FDA on August 27, 2026. Compounding today must be patient-specific, with a prescriber documenting a clinical need the approved product does not meet, and the FDA had logged 990 adverse-event reports for compounded semaglutide and more than 730 for compounded tirzepatide as of May 31, 2026.
When this pathway makes sense: You need medication within days, not weeks. You have predictable monthly income to cover roughly $200 to $300. You're comfortable with non-FDA-approved compounded preparations. You don't qualify for patient assistance due to income level.
When to choose a different pathway: You qualify for free patient assistance. You strongly prefer FDA-approved medications. You can't afford about $200 monthly. You have a compounding pharmacy allergy history.
Pathway 2: Manufacturer patient assistance programs
Novo Nordisk and Eli Lilly both operate patient assistance programs (PAPs) that provide free medication to qualifying low-income patients.
Novo Nordisk PAP (check whether Wegovy is on the current product list; we could not confirm it for this update):
Eligibility (2026):
- Household income below 400 percent of the federal poverty level ($63,840 for an individual, $86,560 for a couple, $132,000 for a family of four under the 2026 HHS poverty guidelines)
- U.S. citizen or legal resident
- No prescription drug coverage through any source (no insurance, no Medicare Part D, no Medicaid, no employer plan)
- Prescription written for chronic weight management with BMI 27+ with comorbidity or BMI 30+
What it provides:
- Free medication for 12 months, renewable annually, for products on the program's current list
- Medication shipped directly to patient's home address
- No copay, no deductible, no out-of-pocket cost
Application process:
- Download forms from NovoCare website
- Provider completes medical necessity section
- Patient completes financial disclosure section
- Submit tax return or pay stub as income verification
- Approval typically takes 7 to 14 business days
Eli Lilly PAP (Lilly Cares; whether Zepbound is covered is disputed, so confirm with the foundation before applying):
Eligibility mirrors Novo Nordisk with minor variations:
- Income below 400% FPL
- No prescription coverage
- BMI 27+ with comorbidity or BMI 30+
The Lilly Cares Foundation processes applications. Approval timeline runs 5 to 10 business days.
The income verification trap:
Most denials happen at income verification, not medical necessity. The programs require documented proof of income. Self-employed patients or those with irregular income face higher denial rates because tax returns show gross income before business expenses, which can push them over the 400 percent FPL threshold even when net income qualifies.
An earlier version of this section cited a 2025 study on PAP denials that we could not locate; it has been removed. The documentation problem is real in our experience, but we have no published percentage for it.
When this pathway makes sense: Your household income falls clearly below 400% FPL. You have standard W-2 employment with straightforward income documentation. You can wait 7 to 14 days for approval. You prefer FDA-approved brand-name medication.
When to choose a different pathway: You need medication immediately. Your income is borderline or documentation is complex. You have any prescription coverage (even a discount card can disqualify you). You're self-employed with high gross but low net income.
Pathway 3: Cash-pay retail pharmacy purchases
Walking into CVS, Walgreens, or Walmart and paying full retail price is the most expensive pathway but requires no eligibility screening beyond a valid prescription.
Manufacturer self-pay prices (seen September 5, 2026), which now undercut every retail cash price this section used to list:
| Medication | Self-pay price | Where | Conditions |
|---|---|---|---|
| Wegovy pen | $199 a month for a new patient's first two fills, then $349; Wegovy HD 7.2 mg $399 | NovoCare pharmacy, Costco Pharmacy (via Sesame), TrumpRx | Introductory price through December 31, 2026; list price $1,349 |
| Wegovy pill | $149 (1.5 mg), $199 (4 mg), $299 (higher strengths) | NovoCare, TrumpRx, Walgreens and CVS programs | Prescription required |
| Zepbound vial or KwikPen | $299 (2.5 mg), $399 (5 mg), $449 (7.5 to 15 mg) | LillyDirect delivery or Walmart pharmacy pickup | Refill within 45 days or $499/$699; list about $1,087 |
| Foundayo pill (orforglipron) | $149 (0.8 and 2.5 mg), $199 (5.5 mg), $299 (9 to 17.2 mg) | LillyDirect | Approved April 1, 2026; 45-day refill rule |
| Ozempic pen | $199 a month | TrumpRx, Costco Pharmacy (via Sesame) | List about $1,028 |
| Generic Saxenda (liraglutide for weight management), 5 pens | About $372 with a GoodRx coupon | Retail pharmacies | Average retail $1,308; brand Saxenda lists at $1,349.02 |
Costco Pharmacy fills Wegovy and Ozempic at the manufacturer self-pay price for members, $349 a month, or $199 for the first two months for new patients on the two lowest doses, with prescriptions available through Sesame (Sesame, November 17, 2025). Membership no longer buys a discount below the manufacturer price; it buys a pickup location.
The 90-day supply strategy:
Some pharmacies offer 90-day supplies at 2.8x to 2.9x the monthly cost (slightly less than 3x due to reduced dispensing fees). This front-loads cost but reduces per-month pricing by $40 to $60.
The 90-day math has changed. With the Wegovy pen at $199 for the first two fills and $349 after, and Zepbound at $299 to $449 through LillyDirect with a 45-day refill rule, there is little reason to pre-buy 90 days at retail; the refill rule actually penalizes long gaps.
When this pathway makes sense: You can pay $149 to $449 for a month at manufacturer self-pay prices. You need medication today or within a few days. You've been denied by patient assistance. You're between insurance coverage (COBRA gap, job transition) and need a 1 to 2 month bridge.
When to choose a different pathway: You cannot afford $149 to $449 a month. You qualify for patient assistance. A compounded price near the $197 to $299 medians is lower for your dose. You're planning treatment longer than 3 months.
Pathway 4: Prescription discount cards and coupons
Discount cards (GoodRx, SingleCare, RxSaver) negotiate lower cash prices with pharmacies. They work like insurance cards but don't require coverage.
How discount cards actually work:
The card company negotiates bulk-rate pricing with pharmacy chains. You present the card at checkout. The pharmacy processes it like insurance, and you pay the negotiated rate. The card company earns a small fee from the pharmacy.
Real pricing with discount cards (September 2026):
| Medication | Retail cash price | GoodRx price | SingleCare price | Savings |
|---|---|---|---|---|
| Wegovy pill | $1,349 list | $149 offer listed on GoodRx | Not captured | The manufacturer self-pay program, not the coupon, sets the price |
| Zepbound KwikPen | About $1,087 list | $299 (GoodRx, September 2026) | Not captured | Same as LillyDirect self-pay |
| Phentermine 37.5 mg, 30 tablets | About $50 average retail | $16 | From $9.91 (September 5, 2026) | Coupons matter most for generics |
For brand GLP-1s, coupons no longer matter much: manufacturer self-pay prices of $149 to $449 sit far below any coupon discount on a $1,000-plus list price, and GoodRx's own listings now simply mirror those programs. Where coupons still matter is generics. Phentermine 37.5 mg drops from about $50 to $10 to $16 for 30 tablets, and generic liraglutide (Victoza equivalent) from about $616 to $112 for two pens.
The deductible trade-off:
Discount card purchases don't count toward insurance deductibles. If you have insurance but haven't met your deductible, using a discount card means that spending doesn't move you closer to your deductible threshold. For patients planning to return to insurance coverage, this creates a hidden cost.
Manufacturer copay cards (different from discount cards):
Novo Nordisk and Eli Lilly offer copay cards that reduce out-of-pocket costs for patients with commercial insurance. These cards do NOT work for uninsured patients. The card reduces a copay, it doesn't replace coverage. Attempting to use a copay card without insurance results in full retail price.
This distinction confuses patients regularly. "Savings card" in manufacturer materials means "copay reduction for insured patients," not "discount for uninsured patients."
When this pathway makes sense: You're paying cash at retail pharmacy anyway. You have 3 minutes to download a free card. You are filling a generic such as phentermine or liraglutide. You're not planning to return to insurance coverage soon.
When to choose a different pathway: You can't afford $900+ monthly even with discount. Compounded options at $179 to $499 are accessible. You're planning to return to insurance and want spending to count toward deductible.
Pathway 5: Clinical trial enrollment
Active clinical trials for weight loss medications occasionally accept uninsured participants and provide free medication, monitoring, and sometimes compensation.
How to find trials:
ClinicalTrials.gov is the federal registry of all U.S. clinical trials. Search terms: "semaglutide weight loss," "tirzepatide obesity," "GLP-1 receptor agonist." Filter by "recruiting" status and your geographic area.
Run the search yourself at ClinicalTrials.gov with the status filter set to recruiting; counts change weekly, so we no longer print one here.
Typical eligibility criteria:
- BMI 30 to 45 (trials often exclude very high BMI due to safety monitoring complexity)
- Age 18 to 65
- No current GLP-1 use
- Willing to attend in-person visits every 2 to 4 weeks
- No major comorbidities (trials exclude patients with recent cardiovascular events, active cancer, severe kidney disease)
What trials provide:
- Free medication for trial duration (typically 6 to 18 months)
- Free lab work, imaging, and medical monitoring
- Sometimes compensation ($50 to $200 per visit)
- Access to medications not yet FDA-approved
The time and commitment trade-off:
Trials require frequent visits. A typical Phase 3 obesity trial requires visits every 2 weeks for the first month, then monthly for 12 to 18 months. Each visit includes vitals, labs, questionnaires, and provider check-ins, typically lasting 60 to 90 minutes.
For employed patients, this means taking time off work twice monthly initially. For patients without transportation, getting to the trial site becomes a barrier.
Randomization risk:
Many trials are placebo-controlled. You might receive placebo instead of active medication. A 2:1 randomization (common in obesity trials) means 67% chance of active drug, 33% chance of placebo. You won't know which group you're in until the trial ends.
When this pathway makes sense: You live near a major research center. You have schedule flexibility for frequent visits. You're comfortable with randomization risk. You want free medication and are willing to contribute to research.
When to choose a different pathway: You need guaranteed active medication now. You can't commit to frequent in-person visits. You live far from trial sites. You need treatment longer than typical trial duration.
Pathway 6: State pharmaceutical assistance programs
Eleven states operate pharmaceutical assistance programs (SPAPs) that help low-income residents afford medications. Coverage for weight loss medications varies by state.
States with active SPAPs (2026):
- Pennsylvania (PACE, PACENET)
- New Jersey (PAAD, Senior Gold)
- Delaware (Prescription Assistance Program)
- Maine (Low Cost Drugs for the Elderly)
- Maryland (Maryland Pharmacy Program)
- Massachusetts (Prescription Advantage)
- Missouri (MO Rx)
- Nevada (Nevada Senior Rx)
- New York (EPIC)
- Rhode Island (Rhode Island Pharmaceutical Assistance)
- Wisconsin (SeniorCare)
Coverage specifics (highly variable):
Pennsylvania PACE covers weight loss medications for patients with documented obesity-related comorbidities (type 2 diabetes, cardiovascular disease) but not for weight loss alone. Income limit: $31,500 for individuals, $41,500 for couples.
Massachusetts Prescription Advantage covers Wegovy and Zepbound with prior authorization showing BMI 35+ with comorbidity or BMI 40+. Income limit: $77,000 for individuals.
Most SPAPs were designed for seniors and require age 65+ or disability status. Younger uninsured patients typically don't qualify.
Application process: State-specific forms available through each state's health department website. Requires proof of residency, income documentation, and prescription. Approval timelines range from 10 to 30 days.
When this pathway makes sense: You live in a state with an active SPAP. You meet age or disability requirements. Your income falls within state limits. You can wait 10 to 30 days for approval.
When to choose a different pathway: Your state doesn't operate an SPAP. You don't meet age/disability requirements. You need medication immediately. You're under income limits for manufacturer PAP (which has broader eligibility).
Pathway 7: Nonprofit medication access foundations
Several nonprofit organizations help patients access medications through grants, copay assistance, or direct medication provision.
Patient Access Network (PAN) Foundation:
Disease-specific funds for obesity and diabetes. Provides copay assistance for patients with insurance and some direct assistance for uninsured patients. Income limits typically 500% of FPL (higher than manufacturer PAPs).
Application through PAN website. Funds are limited and often close when annual budget is exhausted (typically by Q3 each year).
HealthWell Foundation:
Similar model to PAN. Disease-specific funds. Income limits around 500% to 600% FPL. Funds frequently close mid-year.
The Assistance Fund (TAF):
Focuses on chronic disease medications. Obesity fund availability varies by year. Income limits 400% to 500% FPL.
The funding exhaustion problem:
Nonprofit foundations operate on annual budgets. When the obesity fund reaches its cap (often by July or August), applications close until the next fiscal year. A patient applying in September may face "fund closed, reopen January 1" regardless of eligibility.
This creates a timing lottery: the same eligible patient can be approved in February and turned away in September. An earlier version of this paragraph cited a study we could not locate; it has been removed.
When this pathway makes sense: You've been denied by manufacturer PAP due to slightly-too-high income. You're applying early in the calendar year (Q1 or Q2). You have insurance but can't afford copays (some foundations assist insured patients). You can wait 14 to 45 days for approval.
When to choose a different pathway: It's Q3 or Q4 and funds are likely closed. You need medication immediately. You qualify for manufacturer PAP (apply there first). You're far below income limits (manufacturer PAP is faster).
The decision tree: which pathway fits your situation
Start here: What's your household income relative to federal poverty level?
Under 400% FPL ($63,840 individual, $132,000 family of 4 under the 2026 HHS guidelines): → Apply to manufacturer patient assistance program first (Pathway 2) → While waiting for approval (7 to 14 days), start compounded GLP-1 through telehealth (Pathway 1) if you need immediate treatment → If PAP approves, switch to free brand-name medication → If PAP denies, continue compounded or explore state programs (Pathway 6)
400% to 500% FPL: → Check nonprofit foundation eligibility (Pathway 7) → Start compounded GLP-1 (Pathway 1) while foundation application processes → If foundation approves, evaluate whether grant amount makes brand-name affordable → If denied, continue compounded long-term
Above 500% FPL: → Compounded GLP-1 telehealth (Pathway 1) is likely your primary option → Consider clinical trial enrollment (Pathway 5) if you meet criteria and want free medication → Manufacturer self-pay brand (Pathway 3) at $149 to $449 a month if you prefer FDA-approved medication
Special situations:
Between jobs, expecting insurance in 1 to 3 months: → Compounded telehealth (Pathway 1) as bridge → Or discount card retail purchase (Pathway 4) if you need brand-name for continuity
Age 65+ or disabled: → Check state SPAP eligibility first (Pathway 6) → Then manufacturer PAP (Pathway 2) → Then compounded telehealth (Pathway 1)
Live near major research center, schedule flexibility: → Search ClinicalTrials.gov (Pathway 5) → Start compounded telehealth (Pathway 1) while screening for trials
Need medication within 48 hours: → Compounded telehealth (Pathway 1) only → All other pathways require 5+ days minimum
Why Canadian pharmacies and medical tourism fail the risk-benefit test
Online guides frequently mention Canadian pharmacy imports and medical tourism (traveling to Mexico or Canada for cheaper prescriptions) as options for uninsured patients.
Both carry legal and safety risks that outweigh cost savings when safer alternatives exist.
Canadian pharmacy imports:
Federal law prohibits importing prescription medications for personal use, with narrow exceptions for FDA-approved importation programs. As of April 2026, no FDA-approved importation pathway exists for GLP-1 weight loss medications (FDA Import Alerts, 2026).
Patients ordering from Canadian online pharmacies face:
- Customs seizure (medication confiscated at border, no refund)
- Counterfeit medication risk (the FDA has warned about counterfeit and mislabeled GLP-1 products sold online; an earlier statistic here could not be sourced and has been removed)
- No legal recourse if medication causes harm
- Potential federal charges for importing controlled substances (though prosecution of individuals is rare)
Any savings from importing disappeared once U.S. self-pay prices fell to $199 a month for the Wegovy pen and $149 for the pill (September 2026), and compounded semaglutide at a $197 month-1 median provides legal, domestically sourced access without the seizure risk.
Medical tourism:
Traveling to Mexico or Canada to fill prescriptions legally in those countries, then returning to the U.S., creates similar import issues. The medication is legal to purchase in Mexico, illegal to bring across the U.S. border.
Border agents can confiscate prescription medications at land crossings. An earlier version of this paragraph cited a 2025 survey we could not locate; it has been removed.
When these pathways might make sense (rarely):
A patient who travels to Canada frequently for other reasons and can establish care with a Canadian physician might legally use medication while in Canada. But using it in the U.S. after importing remains illegal.
For 99% of patients, the risk-benefit calculation favors legal domestic pathways (compounded telehealth, patient assistance, retail with discount cards) over import/tourism routes.
FormBlends clinical pattern: what we see in 2,400+ uninsured patient journeys
Across 2,400+ patients who started compounded GLP-1 treatment through FormBlends without insurance coverage between January 2024 and March 2026, we see consistent patterns in how uninsured patients access and sustain treatment.
Pattern 1: The combination strategy dominates.
62% of uninsured patients who achieve 6+ months of continuous treatment use a combination approach. They start with compounded semaglutide or tirzepatide for immediate access, then apply to manufacturer patient assistance programs in parallel. If PAP approves (happens in about 35% of applications among our patient population), they switch to free brand-name medication. If denied, they continue compounded long-term.
Single-pathway patients (those who use only one access method) have 40% higher discontinuation rates at 6 months compared to combination-strategy patients.
Pattern 2: Income documentation is the silent barrier.
Among patients who attempt manufacturer PAP applications, income documentation issues cause 3x more denials than actual income disqualification. Self-employed patients, gig workers, and patients with irregular income face the highest denial rates, not because they earn too much but because they can't produce the W-2 or pay stub documentation the programs require.
The programs accept tax returns, but self-employed tax returns show gross revenue before business expenses, which often pushes patients over the 400% FPL threshold even when net income qualifies. A graphic designer earning $75,000 gross with $40,000 in business expenses has $35,000 net income (well under the $63,840 individual limit for 2026) but appears ineligible based on gross revenue.
Pattern 3: Patients underestimate the speed of compounded access.
First-time telehealth patients consistently expect 7 to 10 day timelines based on traditional healthcare experiences. Actual median time from initial consultation to medication delivery is 52 hours. This creates positive surprise but also means patients who delay starting while "researching options" lose weeks of treatment time unnecessarily.
Pattern 4: Costco membership pays for itself, but patients don't know.
Among patients who choose retail cash-pay pathway, only 18% purchase Costco memberships despite Costco's 12% to 15% lower pricing. The $60 membership fee creates a psychological barrier even though it's recovered in savings on the first fill.
When we started proactively mentioning Costco pricing in pre-treatment consultations (late 2025), Costco membership uptake among cash-pay patients increased to 41%.
Pattern 5: Clinical trial interest is high, follow-through is low.
About 30% of uninsured patients express interest in clinical trial participation when presented as an option. Fewer than 5% complete trial screening. The primary dropout point is the visit frequency requirement. Patients underestimate the time commitment until they see the actual visit schedule.
These patterns inform how we structure access conversations. We lead with compounded options for speed, present PAP as parallel track for qualifying patients, mention Costco membership explicitly for cash-pay patients, and set realistic expectations about trial commitment before referring to ClinicalTrials.gov.
The cheapest weight-loss drugs without insurance in September 2026, ranked and dated
The question people actually type is which drug is cheapest. Here is the answer as of September 5, 2026, at the cash prices each source showed, ranked from least to most expensive for a month of the entry dose. Effectiveness rises roughly in the same order, which is the trade-off your prescriber will walk you through.
| Drug | Type | Cash price for a month (entry dose) | Source |
|---|---|---|---|
| Phentermine 37.5 mg (generic) | Daily tablet, stimulant, short-term use | $9.91 to $16 for 30 tablets with a coupon (average retail about $50) | SingleCare (September 5, 2026); GoodRx |
| Lomaira (phentermine 8 mg) | Daily tablet | $15 | GoodRx |
| Diethylpropion, phendimetrazine (generics) | Daily tablets | $35 each | GoodRx |
| Qsymia (phentermine and topiramate) | Daily capsule | $63 | GoodRx |
| Alli (orlistat 60 mg, over the counter) | Capsule with meals | $87 | GoodRx |
| Wegovy pill (semaglutide) | Daily tablet | $149 (1.5 mg); $199 (4 mg); $299 higher strengths | wegovy.com |
| Foundayo (orforglipron) | Daily tablet, approved April 1, 2026 | $149 (0.8 and 2.5 mg); $199 (5.5 mg); $299 (9 to 17.2 mg) | lilly.com |
| Compounded semaglutide | Weekly injection, not FDA approved | Month-1 median $197 (range $88 to $299) | the Compounded GLP-1 Price Index, September 3, 2026 |
| Wegovy pen (semaglutide 2.4 mg) | Weekly injection | $199 for a new patient's first two fills, then $349 | wegovy.com; TrumpRx |
| Contrave (naltrexone and bupropion) | Daily tablet | $199 | GoodRx |
| Generic liraglutide (Victoza equivalent, diabetes dose) | Daily injection | $112 for two pens; $154 to $221 for three | GoodRx; SingleCare (March 18, 2026) |
| Zepbound (tirzepatide) | Weekly injection | $299 (2.5 mg); $399 (5 mg); $449 (7.5 to 15 mg) | lilly.com; GoodRx |
| Compounded tirzepatide | Weekly injection, not FDA approved | Month-1 median $299 (range $149 to $470) | Compounded GLP-1 Price Index |
| Generic Saxenda (liraglutide 3 mg) | Daily injection | About $372 with a coupon | GoodRx |
| Xenical (orlistat 120 mg) | Capsule with meals | $430 | GoodRx |
| Brand Saxenda | Daily injection | $1,324 (GoodRx); list $1,349.02 (NovoCare) | GoodRx; NovoCare |
Three notes. Phentermine is approved for short-term use and is a controlled substance, so telehealth rules differ by state. The GLP-1 prices are entry doses; maintenance doses cost more for Wegovy pens ($349), Zepbound ($399 to $449) and the pills ($299). And the compounded medians come from a live index of telehealth providers, not from FormBlends' own price, which this article does not quote.
Manufacturer self-pay programs replaced the retail cash table
The biggest change since this guide was written is that Novo Nordisk and Lilly now sell directly to cash patients at a fraction of list price. These programs, not pharmacy shelf prices, define Pathway 3 in 2026.
| Program | Products and prices (seen September 5, 2026) | How it works |
|---|---|---|
| NovoCare self-pay (Wegovy) | Pen $199 a month for a new patient's first two fills through December 31, 2026, then $349; Wegovy HD 7.2 mg $399; pill $149, $199 or $299 by dose | Prescription routed to NovoCare pharmacy for home delivery; also offered through Walgreens and CVS programs |
| LillyDirect (Zepbound) | Vial or KwikPen $299 (2.5 mg), $399 (5 mg), $449 (7.5 to 15 mg) when refilled within 45 days; otherwise $499 or $699 | Free home delivery or pickup at nearly 4,600 Walmart pharmacies (launched November 2025); dispensing partners include Amazon Pharmacy, Fuze, Gifthealth and Walmart |
| LillyDirect (Foundayo) | $149 (0.8 and 2.5 mg), $199 (5.5 mg), $299 (9, 14.5 and 17.2 mg) with the 45-day refill rule | Same routing; approved April 1, 2026 |
| TrumpRx | Wegovy pill $149, Wegovy pen $199, Ozempic $199, Zepbound $299 (entry doses; no as-of date shown) | Government-run listing site that links to the manufacturer programs |
| Costco Pharmacy via Sesame | Wegovy and Ozempic $349 a month; $199 for the first two months for new patients on the two lowest doses | Costco membership plus a prescription from Success by Sesame or your own clinician (Sesame, November 17, 2025) |
None of these require insurance, and none exclude Medicare or Medicaid enrollees from paying cash, which is what makes them the realistic Pathway 3 for uninsured patients. The retail cash table this section used to carry ($1,349 for Wegovy, $1,059 for Zepbound) described a market that no longer exists for anyone who knows about these programs.
Patient assistance in 2026: the correct income limits and the Wegovy question
Two corrections to Pathway 2. First, the income thresholds this article carried were 2025 figures. The 2026 HHS poverty guidelines put 400 percent of the federal poverty level at:
| Household size | 400 percent of the 2026 federal poverty level |
|---|---|
| 1 person | $63,840 |
| 2 people | $86,560 |
| 4 people | $132,000 |
Second, whether the weight-loss brands are on the programs' product lists is not something we can confirm from here as of September 5, 2026. NovoCare's patient assistance eligibility page was unreachable when we checked, so Wegovy's inclusion in the Novo Nordisk PAP is unverified, and whether Lilly Cares covers Zepbound is disputed in public sources. Neither program's income rules have changed in principle: household income under 400 percent FPL, U.S. residency, and no prescription drug coverage. Before spending time on an application, call the program or ask your prescriber's office to confirm the drug is on the current list.
If a program does not list the brand you want, the self-pay programs in the previous section are the fallback, and at $149 to $199 a month for the Wegovy pill, Foundayo or the introductory Wegovy pen price they are within reach of many people who would have qualified for free medication only on paper.
If you have Medicare or Medicaid: the Bridge and the state changes
Uninsured in this article means no prescription coverage, but many readers have government coverage that does not cover weight loss. Two things changed in 2026.
- Medicare GLP-1 Bridge. From July 1, 2026 through December 31, 2027, Medicare Part D enrollees who meet BMI criteria and get prior authorization can fill the Wegovy pen or pill, the Zepbound KwikPen or Foundayo for a $50 monthly copay. That spending sits outside the $2,100 Part D out-of-pocket cap (healthinsurance.org). Before July 2026, Part D could not cover these drugs for weight loss at all.
- Medicaid moved the other way. California, New Hampshire, Pennsylvania and South Carolina ended Medicaid coverage of GLP-1s for obesity on January 1, 2026, leaving 13 covering fee-for-service programs in KFF's January 2026 count; Massachusetts followed on July 1, 2026. Coverage for type 2 diabetes, cardiovascular risk reduction and sleep apnea continues everywhere.
- Savings cards are still closed to you. Lilly's and Novo Nordisk's copay cards exclude Medicare, Medicaid, TRICARE and VA patients (zepbound.lilly.com). The manufacturer self-pay programs are not: a Medicaid enrollee can buy Zepbound at $299 to $449 through LillyDirect or the Wegovy pill at $149.
Low-cost prescriber routes
Every pathway on this page starts with a prescription, and for uninsured patients the visit itself is a cost. The cheapest routes we could verify on September 5, 2026:
| Route | Visit cost | What you get | Limits |
|---|---|---|---|
| CVS MinuteClinic weight-loss program | $29 virtual consult (labs extra) | Six medication options including orlistat and Contrave; medications as low as $149 without insurance with a manufacturer coupon | Dose changes about every 4 weeks, follow-up every 3 months |
| Walgreens Virtual Healthcare | $49 video visit, $49 follow-ups | Prescriptions for Wegovy pill (from $149), Wegovy pen ($199 then up to $349), Zepbound KwikPen ($299 to $449), Foundayo ($149 to $299) | Self-pay only; no prior authorization handling; available in 28 states |
| LillyDirect telehealth referral | Set by the independent telehealth provider | Zepbound or Foundayo prescription routed to LillyDirect at self-pay prices | On-label prescriptions only |
| Compounded GLP-1 telehealth | Often bundled into the monthly medication price | Compounded semaglutide or tirzepatide (month-1 medians $197 and $299) | Not FDA approved; patient-specific compounding only since 2025 |
A $29 or $49 visit plus a $149 to $299 medication is a realistic first month for most uninsured patients in 2026. That is the sentence this article could not have written when it was first published.
FAQ
How much does weight loss medication cost without insurance?
As of September 2026, compounded semaglutide has a month-1 median of $197 and compounded tirzepatide $299 across 14 telehealth providers each. Brand self-pay is $199 a month for the Wegovy pen for a new patient's first two fills (then $349), $149 for the Wegovy pill and $299 to $449 for Zepbound through LillyDirect. Patients earning under $63,840 (400 percent FPL, 2026) may qualify for manufacturer patient assistance.
Can I get Wegovy or Zepbound for free without insurance?
Possibly. Novo Nordisk (NovoCare) and Eli Lilly (Lilly Cares) run patient assistance programs for households under 400 percent of the federal poverty level (about $63,840 for an individual and $132,000 for a family of four in 2026) with no prescription coverage. Whether Wegovy and Zepbound are on each program's current product list could not be confirmed for this update, so check before applying. Application takes 7 to 14 days.
What's the cheapest way to get semaglutide without insurance?
Across the 14 telehealth providers tracked in the Compounded GLP-1 Price Index on September 3, 2026, compounded semaglutide ranged from $88 to $299 for the first month with a median of $197. Brand Wegovy self-pay is now $199 a month for the pen (first two fills) and $149 for the pill, so compare your dose and total cost rather than assuming compounding is cheaper.
Do GoodRx coupons work for weight loss medications?
For brand GLP-1s the coupon is beside the point: GoodRx now shows the Zepbound KwikPen at $299 and the Wegovy pill offer at $149, the same as the manufacturer self-pay programs. Coupons matter for generics, cutting phentermine 37.5 mg to about $16 for 30 tablets and generic liraglutide to about $112 for two pens (GoodRx, September 2026).
Can I use the Novo Nordisk savings card without insurance?
No. The Novo Nordisk savings card (and Eli Lilly savings card) only works for patients with commercial insurance. The card reduces your copay, it doesn't replace insurance coverage. Uninsured patients pay full retail price even with the card.
Is compounded semaglutide as effective as Wegovy?
Compounded semaglutide contains the same active ingredient (semaglutide) at the same doses used in clinical trials. The chemical compound is identical. The difference is preparation method (compounding pharmacy vs pharmaceutical manufacturer) and delivery device (vial and syringe vs pre-filled pen). Compounded semaglutide is not FDA-approved as a finished drug product.
How do I qualify for patient assistance programs?
You must have household income below 400% of federal poverty level, no prescription drug coverage from any source, U.S. citizenship or legal residency, and a valid prescription for weight management. Application requires income documentation (tax return or pay stubs) and takes 7 to 14 days to process.
Can I buy Wegovy from Canadian pharmacies legally?
No. Federal law prohibits importing prescription medications for personal use. Canadian pharmacy purchases may be legal in Canada but become illegal when you import them across the U.S. border. Customs agents routinely confiscate prescription medications at border crossings.
What happens if I can't afford medication after starting treatment?
Most providers recommend gradual dose reduction rather than abrupt discontinuation to minimize rebound weight gain. If cost becomes prohibitive, discuss switching to a cheaper route (manufacturer self-pay at $149 to $449, or compounded medians of $197 to $299 as of September 2026), applying for patient assistance, or exploring state pharmaceutical programs. Abrupt discontinuation leads to faster weight regain than gradual taper (Wilding et al., Lancet 2022).
Do clinical trials pay you to participate?
Some trials offer compensation ($50 to $200 per visit) for time and travel, but payment varies by trial. All trials provide free medication, lab work, and medical monitoring. Search ClinicalTrials.gov for specific trial details including compensation information.
Can I switch between compounded and brand-name medication?
Yes, with provider guidance. The active ingredient and dosing are the same, so switching is medically straightforward. The main difference is injection technique (drawing from vial vs using pre-filled pen). Your provider should demonstrate the new injection method when switching.
What if I get insurance after starting compounded medication?
You can switch to brand-name medication if your insurance covers it and the copay is lower than your current compounded cost. Many patients continue compounded medication even after getting insurance because a compounded price near the $197 to $299 medians can be lower than a high copay.
What is the cheapest weight loss drug without insurance?
Generic phentermine 37.5 mg, at about $10 to $16 for 30 tablets with a coupon as of September 5, 2026 (SingleCare, GoodRx), followed by Lomaira ($15), diethylpropion and phendimetrazine ($35) and Qsymia ($63). Among GLP-1s, the Wegovy pill and Foundayo start at $149 a month, compounded semaglutide has a $197 month-1 median, and the Wegovy pen is $199 for a new patient's first two fills. Cheapest and most effective are not the same list; ask your prescriber.
Is there free weight loss medication?
Possibly, through manufacturer patient assistance programs for households under 400 percent of the federal poverty level ($63,840 for an individual, $132,000 for a family of four in 2026) with no prescription coverage, or through clinical trials. Whether Wegovy and Zepbound are on the Novo Nordisk and Lilly Cares product lists could not be confirmed as of September 5, 2026, so check with each program before applying. State assistance programs and nonprofit foundations are mostly limited to seniors or run out of funds mid-year.
How much does a medical weight loss clinic cost without insurance?
Less than most people expect in 2026. CVS MinuteClinic charges $29 for a virtual weight-loss consult (labs extra) and Walgreens Virtual Healthcare $49 per video visit with $49 follow-ups, both self-pay. Medication is separate: $149 to $299 a month for the Wegovy pill or Foundayo, $199 then $349 for the Wegovy pen, $299 to $449 for Zepbound, or compounded GLP-1s near the $197 to $299 medians, often with the consult bundled.
Can I get Wegovy for $199 a month without insurance?
Yes, for the first two fills. As of September 5, 2026, Novo Nordisk's self-pay price for the Wegovy pen is $199 a month for a new patient's first two fills, then $349 a month; the introductory price runs through December 31, 2026, and Wegovy HD 7.2 mg is $399. The Wegovy pill is $149 (1.5 mg), $199 (4 mg) or $299 at higher strengths. TrumpRx and Costco Pharmacy (via Sesame) offer the same pen pricing. No insurance is required.
Related guides
- How to Get Weight Loss Injections Without Insurance: 5 Proven Access Pathways in 2026
- How to Get Insurance to Cover Weight Loss Medication: The 2026 Prior Authorization Strategy That Actually Works
- Can Someone on Medicare Age 64 Get Weight Loss Medication? What's Covered and What's Not
- How Can I Get Mounjaro Cheaper Without Insurance in 2026: 8 Proven Strategies
- What Insurance Plans Cover Weight Loss Medication in 2026: The Complete Coverage Guide
- What Insurance Covers Weight Loss Medication: The 2026 Coverage Reality
- Tool: cost calculator
Sources
- U.S. Food and Drug Administration. Semaglutide and tirzepatide shortage resolutions and compounding policy, December 19, 2024. https://www.fda.gov/media/185577/download
- U.S. Department of Health and Human Services (ASPE). 2026 poverty guidelines. https://aspe.hhs.gov/poverty-guidelines
- Novo Nordisk. What to pay for Wegovy, seen September 5, 2026. https://www.wegovy.com/obesity/what-to-pay-for-wegovy.html
- ClinicalTrials.gov database. GLP-1 receptor agonist obesity trials. Accessed April 2026.
- Wilding JPH et al. Weight regain and cardiometabolic effects after withdrawal of semaglutide. Lancet. 2022;399(10322):1166-1176.
- U.S. Food and Drug Administration. FDA's concerns with unapproved GLP-1 drugs used for weight loss, adverse-event counts as of May 31, 2026. https://www.fda.gov/drugs/postmarket-drug-safety-information-patients-and-providers/fdas-concerns-unapproved-glp-1-drugs-used-weight-loss
- Eli Lilly. LillyDirect Zepbound self-pay pricing (CMAT-05333 08/2026). https://www.lilly.com/lillydirect/zepbound
- Eli Lilly. LillyDirect Foundayo self-pay pricing (CMAT-19155 08/2026). https://www.lilly.com/lillydirect/foundayo
- FDA Import Alerts. Personal importation of prescription medications. Alert 66-41. Updated March 2026.
- Novo Nordisk. NovoCare Patient Assistance Program eligibility criteria. 2026.
- Eli Lilly and Company. Lilly Cares Foundation program guidelines. 2026.
- National Association of State Pharmaceutical Assistance Programs. State program directory. 2026.
- Patient Access Network Foundation. Obesity fund eligibility and application process. 2026.
- GoodRx. Weight loss drugs: prices and coupons, seen September 5, 2026. https://www.goodrx.com/conditions/weight-loss/drugs
- TrumpRx. Wegovy, Ozempic and Zepbound self-pay listings, seen September 5, 2026. https://trumprx.gov
- Sesame. Costco members can get Wegovy and Ozempic for $349 a month, November 17, 2025. https://sesamecare.com/blog/costco-half-price-ozempic-wegovy
- Walmart. LillyDirect and Walmart Pharmacy launch first retail pick-up option for Zepbound, October 29, 2025. https://corporate.walmart.com/news/2025/10/29/lillydirect-and-walmart-pharmacy-launch-first-retail-pick-up-option-with-direct-to-consumer-pricing-for-zepbound
- FormBlends. Compounded GLP-1 Price Index, as of September 3, 2026. https://formblends.com/feeds/glp1-prices.json
- healthinsurance.org. Does health insurance cover drugs used for weight loss? (Medicare GLP-1 Bridge), 2026. https://www.healthinsurance.org/faqs/does-health-insurance-cover-drugs-used-for-weight-loss-such-as-ozempic-wegovy-mounjaro-and-zepbound/
- Williams E. Medicaid Coverage of and Spending on GLP-1s. KFF, January 16, 2026. https://www.kff.org/medicaid/medicaid-coverage-of-and-spending-on-glp-1s/
- Eli Lilly. Zepbound coverage and savings card terms, seen September 5, 2026. https://zepbound.lilly.com/coverage-savings
- SingleCare. Phentermine HCl 37.5 mg prices, updated September 5, 2026 (singlecare.com).
- SingleCare. Is there a generic for Victoza? Prices dated March 18, 2026. https://www.singlecare.com/blog/victoza-generic/
- CVS MinuteClinic. Weight loss program, seen September 5, 2026. https://www.cvs.com/minuteclinic/services/weight-loss-program
- Walgreens Virtual Healthcare. Weight loss, seen September 5, 2026. https://www.walgreens.com/topic/virtual-healthcare/weight-loss.jsp
Footer disclaimers
Platform Disclaimer. FormBlends is a digital health platform that connects patients with licensed providers and U.S.-based pharmacies. We do not manufacture, prescribe, or dispense medication directly. All clinical decisions are made by independent licensed providers.
Compounded Medication Notice. Compounded semaglutide and tirzepatide are not FDA-approved. They are prepared by a state-licensed compounding pharmacy in response to an individual prescription. Compounded medications have not undergone the same review process as FDA-approved drugs and are not interchangeable with brand-name products.
Results Disclaimer. Individual results vary. Weight-loss outcomes depend on diet, exercise, adherence, baseline weight, and individual response to treatment. Statements about average outcomes reference published clinical trial data, which may differ from real-world results.
Trademark Notice. Wegovy, Ozempic, Rybelsus, and Saxenda are registered trademarks of Novo Nordisk A/S. Zepbound and Mounjaro are registered trademarks of Eli Lilly and Company. GoodRx, SingleCare, Costco, Walmart, and CVS are trademarks of their respective owners. FormBlends is not affiliated with, endorsed by, or sponsored by any of these companies.
See your options in about 2 minutes
Take the free quiz and see what fits you. Quick, private, and no commitment to continue.
See my options →